PA-BENTLEY-SYSTEMS
9.7.2020 15:33:09 CEST | Business Wire | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced that its Acceleration Fund has invested in launching Virtuosity , a Bentley company. Virtuosity exclusively offers Virtuoso Subscriptions that bundle — with a Bentley infrastructure modeling, simulation, or construction application — the virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005552/en/
Virtuoso Subscriptions are now available, at virtuosity.com , for Bentley applications including MicroStation , OpenBridge , OpenBuildings , OpenFlows , OpenRail , OpenRoads , OpenSite , OpenTower , OpenWindPower , AutoPIPE , ContextCapture , LEGION , MOSES , PLAXIS , RAM , SACS , SoilVision , STAAD , and SYNCHRO , and Bentley’s iTwin Design Review cloud service. Virtuosity’s expert services, accessible through Virtuoso Subscription “keys,” include a range of training and one-to-one mentoring activities, and on-demand learning and content, increasingly integrated during actual application usage.
Allan Murphy, Virtuosity CEO, said, “The world’s infrastructure professionals have all gained a new appreciation for what can be achieved through online collaboration. We think this is the perfect time to inaugurate our commercial innovation: a virtuoso subscription that enhances the functionality of a software application through intrinsic assistance from subject matter experts. We’re marshalling and virtualizing our domain expertise to help every infrastructure practitioner perform with the confidence of a virtuoso!”
Werner Felber, Managing Partner, Boley Geotechnick GmbH, Beratende Ingenieure, said, “With Virtuoso Subscriptions, professionals across our international teams can support projects more effectively. Virtuosity’s experts will help keep us current in going digital by constantly leveraging what’s new in Bentley’s applications to ensure our competitiveness in the market and the best results for our customers.”
Image: Virtuosity logo
Image: Allan Murphy headshot
YouTube video: The Value of a Virtuoso Subscription
About Virtuosity, a Bentley Company
Virtuosity
is the exclusive global provider of Virtuoso Subscriptions
for Bentley Systems’ infrastructure modeling, simulation, and construction applications. Every Virtuoso Subscription—procured through the ecommerce site virtuosity.com
—uniquely bundles, with a Bentley software application, virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
About Bentley Systems’ Acceleration Fund
Bentley Systems’ Acceleration Fund was founded in 2020 to invest in new and incremental participants in open ecosystems to advance infrastructure digital twins. The Bentley Systems Acceleration Fund is chartered to accelerate the creation and curation of digital twins, and to foster technologies and innovations so enabled, by nurturing new ventures, making minority investments, and acquiring and expanding digital integrators. Investments to date include Digital Water Works, Digital Construction Works, Virtuosity, and The Cohesive Companies. Chief Acceleration Officer Santanu Das welcomes queries from potential ecosystem participants at www.bentleyaccelerationfund.com
.
About Bentley Systems
Bentley Systems is a leading global provider of software solutions to engineers, architects, geospatial professionals, constructors, and owner-operators for the design, construction, and operations of infrastructure. Bentley’s MicroStation
-based engineering and BIM applications, and its digital twin cloud services, advance the project delivery (ProjectWise
) and the asset performance (AssetWise
) of transportation and other public works, utilities, industrial and resources plants, and commercial and institutional facilities.
Bentley Systems employs more than 3,500 colleagues and generates annual revenues of more than $700 million in 172 countries. From inception in 1984, the company has remained majority-owned by its five founding Bentley brothers. www.bentley.com
Bentley, the Bentley logo, Bentley Acceleration Fund, AssetWise, AutoPIPE, ContextCapture, iTwin, LEGION, MicroStation, MOSES, OpenBridge, OpenBuildings, OpenFlows, OpenRail, OpenRoads, OpenSite, OpenTower, OpenWindPower, PLAXIS, ProjectWise, RAM, SACS, SoilVision, STAAD, SYNCHRO, Digital Water Works, The Cohesive Companies, Virtuosity, and Virtuoso Subscription are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005552/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom